Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Deep Brain Stimulation of the Bilateral Nucleus Accumbens for Patients With Methadone Maintenance Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03952455
Recruitment Status : Recruiting
First Posted : May 16, 2019
Last Update Posted : May 17, 2019
Sponsor:
Information provided by (Responsible Party):
Bomin Sun, Ruijin Hospital

Brief Summary:

Methadone maintenance treatment (MMT) is one of the main forms of treatments for opioid dependence. Despite its effectiveness and widespread use, people will experience withdrawal if daily dose is insufficient or missed, promoting reluctance to attempt detoxification. In addition, methadone is a full opioid agonist which can induce respiratory depression or sedation without ceiling level, so overdose usage can be fatal. Hence, an alternative therapy is needed to completely reduce the carving for drugs and to relieve the negative affective sate caused by withdrawal.

Deep brain stimulation (DBS) is a reasonable treatment approach for addiction. Since 2009 the first case report emerged, the nucleus accumbens (NAc) is still the only brain target to be investigated in clinical case series of DBS for alcohol and heroin addiction.

This research will mainly investigate the effectiveness and safety of NAc-DBS for patients with methadone maintenance treatment. The investigators will also explore the influence of NAc-DBS on brain activity and cognition.


Condition or disease Intervention/treatment Phase
Addiction Opiate Procedure: Bilateral surgical implantation of DBS system to Nucleus Accumbens Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Deep Brain Stimulation of the Bilateral Nucleus Accumbens for Patients With Methadone Maintenance Treatment
Estimated Study Start Date : May 15, 2019
Estimated Primary Completion Date : June 1, 2021
Estimated Study Completion Date : June 1, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: DBS
All subjects will undergo bilateral surgical implantation of DBS system in the Nucleus Accumbens. The DBS system will be active at two days after surgery.
Procedure: Bilateral surgical implantation of DBS system to Nucleus Accumbens
We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).




Primary Outcome Measures :
  1. Changes in Methadone dose [ Time Frame: Baseline (preoperative),1 month, 3 months,6 months,9 months, 12 months ]
    The volume of daily methadone the patients used.


Secondary Outcome Measures :
  1. Hamilton Depression Scale(HAMD-17) [ Time Frame: Baseline(preoperative),1 month, 3 months, 6 months, 9 months, 12 months ]
    17 items, Total scores<7: normal; 7<Total scores≤17: possible depression; 17<Total scores≤24: definite depression; Total score>24: severe depression

  2. Hamilton Anxiety Scale (HAMA) [ Time Frame: Baseline(preoperative),1 month, 3 months, 6 months,9 months, 12 months ]
    14 items, Total scores<6: normal; 7<Total scores≤14: possible anxiety; 14<Total scores≤21:definite anxiety; Total score>21: severe anxiety

  3. Young Manic Rating Scale (YMRS) [ Time Frame: Baseline(preoperative),1 month, 3 months, 6 months,9 months, 12 months ]
    The Young Mania Rating Scale (YMRS) is one of the most frequently utilized rating scales to assess manic symptoms. The scale has 11 items and is based on the patient's subjective report of his or her clinical condition.

  4. Monitoring of Side Effects Scale (MOSES) [ Time Frame: Baseline(preoperative),1 month, 3 months, 6 months,9 months, 12 months ]
    To evaluate side effects. The higher score means more severity of side effects.

  5. Changes in Subjective Opiate Withdrawal Scale(SOWS) [ Time Frame: Baseline(preoperative),1 month, 3 months, 6 months,9 months, 12 months ]
    Subjective Opiate Withdrawal Scale is a 16-item self-reported scale assessing severity of opiate withdrawal. Each item is rated on a 5-point Likert scale, ranging form 0(not at all) to 4(extremely).

  6. Obsessive compulsive drug use scale(OCDUS) [ Time Frame: Baseline(preoperative),1 month, 3 months, 6 months,9 months, 12 months ]
    Obsessive compulsive drug use scale is a 13-item self-rating scale measuring opiate craving. The total score ranges from 0 to 52. The higher score indicates stronger carving.

  7. The MOS item short from health survey (SF-36) [ Time Frame: Baseline(preoperative),1 month, 3 months,6 months,9 months, 12 months ]
    36 items. To evaluate the quality of life and the higher score indicates better quality of life.

  8. World Health Organization Quality of Life-BREF (WHO-BREF) [ Time Frame: Baseline(preoperative),1 month, 3 months,6 months,9 months, 12 months ]
    26 items. The higher score means the better quality of life.

  9. Fagerstrom Test for Nicotine Dependence assessment (FTND) [ Time Frame: Baseline(preoperative),1 month, 3months,6months,9 months, 12 months ]
    To evaluate Nicotine Dependence. The higher of scores indicates higher level of Nicotine Dependence

  10. Beck depression inventory(BDI) [ Time Frame: Baseline(preoperative),1 month, 3months,6months,9 months, 12 months ]
    The BDI contains 21 questions, each answer scored on a scale value of 0 to 3. 0-13: minimal depression;14-19:mild depression; 20-28:moderate depression; and 29-63:severe depression. Higher total score indicate more severe depressive symptoms.

  11. Beck anxiety inventory(BAI) [ Time Frame: Baseline(preoperative),1 month, 3months,6months,9 months, 12 months ]
    The BAI contains 21 questions, each answer scored on a scale value of 0 to 3. 0-21: mild anxiety;22-35: moderate anxiety;36-63:severe anxiety. Higher total score indicate more severe anxiety symptoms.

  12. Perceived stress scale(PSS-10) [ Time Frame: Baseline(preoperative),1 month, 3months,6months,9 months, 12 months ]
    The PSS-10 is a classic stress assessment instrument. Each item is rated on a 5-likert scale ranging form 0(never) to 4(often). Higher score indicate more severity of stress symptom.

  13. Twenty Item Positive and Negative Affect Schedule (PANAS) [ Time Frame: Baseline(preoperative),1 month, 3months,6months,9 months, 12 months ]
    The PANAS contains two subscales: positive and negative subscale. Each item is rated on a 5-likert scale ranging from 1(Not at all) to 5(severely, it bothered me a lot).

  14. Work and Social Adjustment Scale(WSAS) [ Time Frame: Baseline(preoperative),1 month, 3months,6months,9 months, 12 months ]
    Self-rated scale. The maximum score of the WSAS is 40, lower scores are better.

  15. Cognitive performance [ Time Frame: Baseline(preoperative),6 months,12 months ]
    Cognitive performance is measured by a series of tasks which include stop signal task, paired associated memory, spatial working memory, stocking of Cambridge, intra-extra dimensional set shift, Bart, Beads, Delay discounting task, model-based and model-free task, avoid-approach task, dot-probe task, drug rating task.

  16. Brain activity [ Time Frame: Baseline(preoperative), 6 months,12 months ]
    PET(Positron Emission Tomography) or fMRI(functional Magnetic Resonance Imaging) are used in this study.


Other Outcome Measures:
  1. Barratt impulsiveness scale [ Time Frame: Baseline(preoperative) ]
    The Barratt Impulsiveness Scale is a questionnaire designed to assess the personality/behavioral construct of impulsiveness which is composed of 30 items describing common impulsive or non-impulsive (for reverse scored items) behaviors and preferences. It has three 2nd order facets which are attentional, motor and non-planning. Each facet has 10 items. Higher score means greater impulsivity.

  2. UPPS-P impulsive behavior scale [ Time Frame: Baseline(preoperative) ]
    The UPPS-P Impulsive Behavior Scale is a 59-item questionnaire assessing impulsive personality traits. Each item is rated on a 4-point scale ranging from 1 (agree strongly) to 4 (disagree strongly) to indicate subject's agreement with statements. This scale includes the following five subscales: negative urgency (NU), lack of premeditation (LPM), lack of perseverance (LPS), sensation seeking (SS) and positive urgency (PU). Higher score represents a greater level of impulsivity.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • MINI diagnosis of substance dependence;
  • Proficiency in Mandarin language;
  • Failure to detox more than three times;
  • Long-term methadone maintenance treatment;
  • Capacity to provide informed consent (understanding of the study purpose and methods);

Exclusion Criteria:

  • Schizophrenia(MINI diagnosis);
  • Antisocial personality disorder(MINI diagnosis);
  • Contraindications of a MRI-examination, e.g. implanted cardiac pacemaker/heart defibrillator;
  • Severe cognitive impairments(MoCA ≤ 22);
  • Enrollment in other clinical trials;
  • Stereotactic respectively neurosurgical intervention in the past;
  • Contraindications of stereotactic intervention, e.g. increased bleeding disposition, cerebrovascular diseases (e.g. arteriovenous malfunction, aneurysms, systemic vascular diseases);
  • Serious or instable organic diseases (e.g. instable coronal heart disease);
  • Tested positively for HIV;
  • Pregnancy and/or lactation;
  • Epilepsy or other severe brain trauma or neurological impairments;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03952455


Locations
Layout table for location information
China, Shanghai
Shanghai Ruijin Hospital Functional Neurosurgery Recruiting
Shanghai, Shanghai, China, 200025
Contact: Chencheng Zhang, MD    +086-18217122884    i@cczhang.org   
Contact: Yingying Zhang, MSc    +086-17602137369    zhyy019@126.com   
Sponsors and Collaborators
Ruijin Hospital

Publications:
Layout table for additonal information
Responsible Party: Bomin Sun, Director of the Department of Functional Neurosurgery, Ruijin Hospital
ClinicalTrials.gov Identifier: NCT03952455     History of Changes
Other Study ID Numbers: 2019 NAc-DBS MMT
First Posted: May 16, 2019    Key Record Dates
Last Update Posted: May 17, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Bomin Sun, Ruijin Hospital:
Nucleus Accumbens
Deep brain stimulation
Methadone

Additional relevant MeSH terms:
Layout table for MeSH terms
Methadone
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Antitussive Agents
Respiratory System Agents